• Loading stock data…

Trastuzumab Deruxtecan Type II Variation Application Validated by EMA for Patients with HER2 Positive Metastatic Breast Cancer Treated with a Prior Anti-HER2-Based Regimen

[#item_full_content]

Print Friendly, PDF & Email
Spread the word